Business Context and Reporting Period
This Form 6-K filing by CollPlant Biotechnologies Ltd. covers the period ending February 8, 2021. The report details a strategic collaboration entered into on February 5, 2021, between CollPlant Ltd. (a wholly-owned subsidiary) and subsidiaries of AbbVie Inc. The agreement focuses on the development and commercialization of dermal and soft tissue filler products for the medical aesthetics market using CollPlant's recombinant human collagen (rhCollagen) technology.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period. The financial significance of this filing is derived from the potential future cash flows outlined in the new agreement:
- Upfront Payment: $14 million cash payment for Exclusive Products.
- Exclusive Products Milestones: Up to $36 million in proceeds upon achieving development, clinical, regulatory, and commercial milestones.
- Option Products Potential: Up to $53 million total, including $6 million for an injectable breast implant agreement, $4 million for a photocurable dermal filler agreement, and up to $43 million in milestones.
- Ongoing Revenue: Fixed-fee royalty payments on commercial sales and fees for the supply of rhCollagen.
Material Changes
The primary material change is the execution of the Development, Exclusivity and Option Products Agreement with AbbVie. This grants AbbVie worldwide exclusive rights to use CollPlant's rhCollagen for specific medical aesthetics products. CollPlant has agreed not to research, develop, or commercialize its rhCollagen for these exclusive products or grant conflicting rights to third parties during the agreement term.
Outlook, Risks, and Contingencies
Outlook and Management Commentary: The agreement establishes a long-term partnership with a supply agreement to be finalized later. The term continues until the later of patent expiration or 10 years from the first commercial sale of a product in a specific country. Rights become non-exclusive and royalty-free after expiration.
Risks and Contingencies:
- Termination Rights: AbbVie may terminate immediately if it perceives a serious safety issue regarding the products. AbbVie may also terminate for any reason with 60 days' written notice on a product-by-product or country-by-country basis.
- Milestone Dependency: The majority of the potential $50 million (Exclusive) and $53 million (Option) payments are contingent upon achieving specific development, clinical, regulatory, and commercial milestones.
- General Termination: Either party may terminate for material breach or bankruptcy.
Investor Verification Checklist
- Verify the exact timing and conditions for the $14 million upfront payment receipt.
- Review the specific definitions of the development and commercial milestones required to unlock the $36 million and $43 million in potential proceeds.
- Assess the impact of AbbVie's broad termination rights (including the 60-day "for any reason" clause) on the stability of future revenue streams.
- Confirm the status of the future supply agreement and the pre-agreed pricing mechanism for rhCollagen.
- Monitor the progress of the aseptic process development project as the initial deliverable under the agreement.